- PROJECT 4 Emerging evidence has implicated transcriptional coactivators and enhancer elements as having a central role in the pathogenesis of human cancer. The research outlined in Project 4 will develop transcriptional coactivators as proteins that support the aberrant capabilities of cancer cells, thus revealing a novel class of epigenetic drug targets in oncology. This research will explore the role of SWI/SNF and TFIID coactivator complexes in the pathogenesis of Acute Myeloid Leukemia (AML) and will identify novel roles for coactivators in supporting the progression of late-stage Pancreatic Ductal Adenocarcinoma (PDA).
The first Aim of this proposal will analyze the anti-leukemia effects of chemical inhibitors of the bromodomain of BRD9, which are novel compounds we generated in collaboration with Boehringer-Ingelheim. The major objective of this research will be to develop drug combinations that augment the therapeutic effects of BRD9 inhibition in AML. This will include use of CRISPR-scanning and domain-focused CRISPR screening, which are recently developed genetic tools to allow deep mechanistic investigation of endogenous protein complexes and to reveal opportunities for drug repurposing. This research has a direct potential to motivate clinical studies of novel drug combinations in AML patient populations.
The second Aim will develop the TAF12/TFIID complex as a novel dependency in AML and reveal its underlying mechanism in supporting oncogene-mediated leukemic transformation. This will also include identifying suitable routes for direct chemical inhibition of this complex, an objective that has yet to be achieved in the cancer epigenetics field, largely owing to our incomplete understanding about how TFIID supports cancer pathogenesis.
The third Aim of Project 4 will be to understand how modulation of nucleosome structure by writers, readers, and erasers of post-translational histone marks might endow PDA cells with the capacity to undergo metastasis. This will include domain- focused CRISPR screening to interrogate chromatin regulators that allow distal metastasis in mouse models of PDA. Since early metastasis is a major contributor to the high mortality of PDA patients, this research may significantly impact our basic understanding of the lethal form of this disease, and carries the potential for revealing epigenetic drug targets for this malignancy. Importantly, the research outlined in Project 4 will provide a deep mechanistic investigation of transcriptional mechanisms that support AML and PDA, which will rely on extensive use of epigenomic tools (e.g. ChIP-seq-based measurement of enhancer activity), and biochemical approaches. Project 4 will also feature extensive collaborations with the other Projects and Cores to evaluate molecular mechanisms and in vivo biology of malignant cells. This basic research will reveal novel vulnerabilities in lethal malignancies, which could provide new routes for therapy.

Public Health Relevance

- PROJECT 4 This research will develop a new class of therapeutic targets for the treatment of two lethal cancers: acute myeloid leukemia and pancreatic cancer. Experiments will provide insight into how novel therapies exert their harmful effects on cancer cells and will provide pre-clinical proof-of-concept in animal models that could justify clinical investigation in cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA013106-46A1
Application #
9417200
Study Section
Special Emphasis Panel (ZCA1)
Project Start
1997-02-10
Project End
2023-01-31
Budget Start
2017-09-01
Budget End
2018-08-31
Support Year
46
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Cold Spring Harbor Laboratory
Department
Type
DUNS #
065968786
City
Cold Spring Harbor
State
NY
Country
United States
Zip Code
11724
Tarumoto, Yusuke; Lu, Bin; Somerville, Tim D D et al. (2018) LKB1, Salt-Inducible Kinases, and MEF2C Are Linked Dependencies in Acute Myeloid Leukemia. Mol Cell 69:1017-1027.e6
Xu, Yali; Milazzo, Joseph P; Somerville, Tim D D et al. (2018) A TFIID-SAGA Perturbation that Targets MYB and Suppresses Acute Myeloid Leukemia. Cancer Cell 33:13-28.e8
Huang, Yu-Han; Klingbeil, Olaf; He, Xue-Yan et al. (2018) POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes Dev 32:915-928
Livshits, Geulah; Alonso-Curbelo, Direna; Morris 4th, John P et al. (2018) Arid1a restrains Kras-dependent changes in acinar cell identity. Elife 7:
Tiriac, Hervé; Belleau, Pascal; Engle, Dannielle D et al. (2018) Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov 8:1112-1129
Bhagwat, Anand S; Lu, Bin; Vakoc, Christopher R (2018) Enhancer dysfunction in leukemia. Blood 131:1795-1804
Banito, Ana; Li, Xiang; Laporte, Aimée N et al. (2018) The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. Cancer Cell 34:346-348
Skucha, Anna; Ebner, Jessica; Schmöllerl, Johannes et al. (2018) MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity. Nat Commun 9:1983
Banito, Ana; Li, Xiang; Laporte, Aimée N et al. (2018) The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. Cancer Cell 33:527-541.e8
Lin, Kuan-Ting; Ma, Wai Kit; Scharner, Juergen et al. (2018) A human-specific switch of alternatively spliced AFMID isoforms contributes to TP53 mutations and tumor recurrence in hepatocellular carcinoma. Genome Res :

Showing the most recent 10 out of 610 publications